Pharma Capital

'A very big day for us indeed', says SkinBio's Dr Cath O'Neill as they begin trading on AIM

''It's a very big day for us indeed'', says Dr Cath O'Neill, chief executive of SkinBio Therapeutics (LON:SBTX) as the company kicks off trading on London's AIM.

''We're aimed at products for skin in health and disease and this is based on a technology that came out of The University of Manchester''.

 

View full SBTX profile

SkinBioTherapeutics PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.